Download - Asthma
![Page 1: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/1.jpg)
Asthma
![Page 2: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/2.jpg)
• Asthma is a chronic inflammatory disorder of airways.
• The expression of asthma results of a complex interrelationship of genetic susceptibility & environmental influences.
• Multiple factors that trigger bronchospasm, include:-allergens-emotions -environment(weather changes, smoke) -exercise-respiratory infections
![Page 3: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/3.jpg)
![Page 4: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/4.jpg)
![Page 5: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/5.jpg)
![Page 6: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/6.jpg)
![Page 7: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/7.jpg)
• Signs & Symptoms :1. Chronic Asthma:
- Shortness of breath/ dyspnea- Wheezing- Cough- Sputum - Chest tightness
**Occur continuously or episodic.
![Page 8: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/8.jpg)
• Treatment recommendation of chronic asthma is based on its classification:* Mild intermittent* Mild persistent* Moderate persistent* Severe Persistent
![Page 9: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/9.jpg)
2. Acute Asthma:• Signs/symptoms are similar to chronic .• Additional S/S may also be present, i.e.:
-Tachypnea-Tachycardia-Retractions-Cyanosis-Hypoxemia
• Sudden onset occurs in :acute, exacerbations, status asthmaticus.
![Page 10: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/10.jpg)
• S/S may progress over hours, days, weeks before reaching functional deterioration.
• Eosinophils in the airways indicates allergic component.
• Typical triggers: * Allergens * Exercise
* Psychological stress
![Page 11: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/11.jpg)
3. Exercise-Induced Bronchospasm: • Transient narrowing of airways after vigorous
exercise.
• Cold-dry air provokes EIB.
• In EIB, a reduction of @ least 15% in FEV1following exercise.
![Page 12: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/12.jpg)
4. Nocturnal Asthma:
• In normal diurnal variation, the lung function reaches its peak @ 4 PM & reaches its minimum @ 4 AM.
• Symptoms of dyspnea & cough may waken the patient requiring a bronchodilator treatment.
• GERD, Obesity, & increased age are associated with nocturnal asthma.
• Evaluation is important for treatment guidelines.
![Page 13: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/13.jpg)
5. PMS Asthma:• Asthma symptoms increase in days before & during menses in asthmatic
patient by an unknown mechanism.
• May be due to usual increase in Beta-2 receptor density during the Luteal phase of the menstrual cycle in non-asthmatic females which is absent in PMS asthma.
• Treatment includes:-Hormones-Leukotriene antagonists-ICS-LABA
![Page 14: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/14.jpg)
• Diagnosis:- Based on : 1.Clinical History
2.PFTs ( Objective Measures )-Recurrent Exacerbations may be provoked by:
*Viral Resp. Infections*Psychological Factors*Allergens*Irritants (Dry powders, Chemicals,…)
*Exercise*Hx of nocturnal Symptoms*Meds. ( ASA, NSAID,…)
-Physical exam maybe normal.
![Page 15: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/15.jpg)
• Other allergic symptoms may be present with allergic (atopic) asthma, include:-Rhinitis-Sinusitis-Eczema-Blood eosinophilia-Sputum eosinophilia
• Allergen exposure leads to:a. Immediate (Early) asthmatic response (IAR): decreased PFT within minutesb. Late asthmatic response (LAR):
2nd decrease in PFT several hours of exposure.
![Page 16: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/16.jpg)
• Spirometry:1. FEV1: - Most commonly used spirometric evaluation of pulm. function.
- Volume of air expelled within 1st second of forced expiration after max.
inhalation.2. PEF: - Max. rate @ which air is exhaled from lungs
with forced expiratory maneuver. - Correlates well with FEV1 - Accurate & obj. self-monitoring of pulm. functions by simple portable inexpensive peak flow-meter.
Disadvantage: Dependent of patient effort.
![Page 17: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/17.jpg)
• Assessment of Allergy:• 60-78% of asthma in adults has allergic
component.• Up to 93% of asthma in children has allergic
component.* Allergen prick skin is the most commonly diagnostic
test for atopy, & patient should takeoral antihistamine before test.
* Tx : Anti IgE Monoclonial Antibody.
![Page 18: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/18.jpg)
• Chest X-Ray:• Normal in mild disease.• Hyperinflation in severe chronic asthma.Therapeutic Plan:Treatment Guidelines:4 Major Components of Asthma Management: 1.Use of objective measures to assess & monitor2.Control factors contributing to severity.3.Use of optimal pharmacological therapy.4.Provide patient education & develop partnership in asthma
care.
![Page 19: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/19.jpg)
• Goals of Asthma Management:1. Maintain normal activity levels.2. Maintain (near) normal PFTs.3. Prevent chronic & troublesome symptoms.4. Prevent recurrent exacerbation of asthma & min.
need for emergency dept. visits or hospitalization.5. Provide optimal pharmacotherapy with min. or no
side effects.6. Meet patients’ & families’ expectations of satisfaction
with asthma care.
![Page 20: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/20.jpg)
• Recommended Use of Spirometry:
1. At the time of diagnosis (for pts. >5 y.o.)for assessing severity & reversibility.
2. Following initiation of treatment after S/Sstabilize (effectiveness & response).
3. At least every 1-2 yrs. to monitor disease progression.
![Page 21: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/21.jpg)
![Page 22: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/22.jpg)
![Page 23: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/23.jpg)
I. Long-Term Treatment:• Recommended treatment is based on :
Persistence & Severity of symptoms.
**Refer to Guidelines of Stepwise approach to Treatment of Chronic Asthma.
![Page 24: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/24.jpg)
![Page 25: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/25.jpg)
![Page 26: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/26.jpg)
![Page 27: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/27.jpg)
• Only Mild intermittent (Step1) does not require long-term treatment.
• All asthma patients should use SABA for acute symptoms.
• Recommendation: All asthma patients should receive action plan for daily long-term meds. & for what to do in acute exacerbation of asthma.
![Page 28: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/28.jpg)
• Anti-inflammatory meds. esp. ICS are the cornerstone of long-term daily therapy for persistent asthma.
• As monotherapy, ICS is > effective than cromoly, leuk. Modifiers, nedocromil, & theophylline.
• Rescuers: SABA & systemic corticosteroids• Controllers: All others & oral corticosteroids
![Page 29: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/29.jpg)
• ICS : the only long-term controller shown to reduce risk of death from asthma.
• Persistent asthma pts. should not use regular administration of SABA or LABA as long-term controller monotherapy.
• ICS + LABA combination is more effective than doubling ICS dose.
• If the pt. has hx of frequent severe exacerbations increase ICS dose + LABA
![Page 30: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/30.jpg)
• 4 times increase in ICS dose may be required to produce significant reduction in asthma exacerbation.
• Adding any one of the alternatives to ICS( if pt. can not tolerate LABA ) is as effective as doubling the ICS dose.
![Page 31: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/31.jpg)
• Many prescribe severe persistent asthma pt. a 3rd long-term controller before starting oral corticosteroid.
• Current Evidence does not support additional benefit from adding 3rd or 4th long-term controllers.
• Patients with severe atopic (allergic) asthma & high IgE conc. could discontinue oral corticosteroid following Omalizomab therapy.
![Page 32: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/32.jpg)
II. Acute Asthma:• All levels of severities are @ risk of acute exacerbation even
if well-controlled on long-term controllers ( if exposed to specific triggers).
• Fig. 34.5 p.889: Home Management of Acute Exacerbation.
• Fig. 34.6 p. 891: Treating Acute Exacerbation of Asthma in E.R. or Hospital.
• Table 35.4 p.894: Recommended Doses for Severe Acute Asthma
![Page 33: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/33.jpg)
![Page 34: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/34.jpg)
![Page 35: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/35.jpg)
• SABAs are the most effective quick relief (rescue) meds. • No advantage of nebulizer over MDI + spacer.• Parenteral SABA should NOT be used due to increased S/Es
without increasing efficacy.
• Short Acting Anticholinergic Ipratropium Br.is used only for those:
1)intolerant to SABA or 2)not completely responding to usual doses of SABA in E.R., adding Ipratropium Br. to SABA reduces the risk of hospitalization.
![Page 36: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/36.jpg)
• Most asthma exacerb. pts. @ E.R. or clinic respond adequately to 1st 3 doses of SABA& can be discharged.
• It is recommended that inadequate response to initial bronchdilators (SABA & Ach) should be started on systemic corticosteroid p.o. or I.V. (No advantage in efficacy of either one).
• ICS is NOT as effective as systemic corticosteroid in severe acute asthma, but adding ICS to the usual short course systemic corticosteroid, prevents relapse following discharge from E.R.
![Page 37: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/37.jpg)
• Nondrug Management of Severe Acute Asthma:
1. Low flow O₂ therapy by nasal canulae to prevent hypoxemia.
2. Pulse oximetry 3. O₂ flow to mainaitn O₂ Saturation≥90%.4. In very severe cases, ABGs are used to
monitor pCO₂ if it is normal to increased after intensive therapy due to risk of resp. failure.
5. All pts. should measure their PEF after initial SABA.
![Page 38: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/38.jpg)
• Pediatric Treatment in Acute Asthma:
• In acute severe asthma, treatment is similar to adults with dose differences.
• As alternatives in pediatric treatment of chronic asthma, leuk.modifiers & cromolyn are safer than theophylline.
![Page 39: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/39.jpg)
• Pharmacotherapy:• Treatment includes providing optimal pharmacotherapy with min.
or no ADRs.• Meds. for asthma: 1. Bronchdilators
&2. Anti-inflammatory*Rescuers/ “Quick- relief agents”:
1. SABA2. Acholinergic3. Short-term systemic corticosteroids
* Controllers / “Long-term control agents”:Inhaled or oral corticosteroids, cromolyn, nedocromil, LABA, theoph., leukot. modifiers.
![Page 40: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/40.jpg)
I. Bronchodilators:1) Beta-2 adrenergic agonists:
-Safest & most effective bronchodilatorsa. SABA: - Albuterol b. LABA: - Salmeterol - Bitolterol - Formoterol
- Metaproterenol - Pirbuterol - Terbutaline
![Page 41: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/41.jpg)
• Increasing the use of SABA can be a marker of poor asthma control, & ICS should be added or increased in dose.
* Guidelines recommend SABA to be used as: 1) prn for intermittent symptoms.
or 2) 1st line therapy for severe acute asthma.
• In severe asthma, SABA is administered as:-MDI + spacer-Intermittent nebulizer-continuous nebulizer
• There is NO difference in efficacy between the 3 methods.
• I.V. SABA is NOT recommended
• No difference was shown in the efficacy between cont. & intermittent SABA delivery for adults, however, ICU asthma children showed greater improvement with cont. nebulizer albuterol.
![Page 42: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/42.jpg)
• SABA : - The treatment of choice to prevent exercise-induced asthma (EIA).
-Provides 4-hr duration when given just before exercise.
• LABA: - Recommended for persistent asthma only in combination with ICS (NOT monotherapy).
- Both LABAs are indicated for preventing EIA when used 15-30 min before long exercise.
- In combination with ICS, LABA controls EIA for up to 12 hrs.
![Page 43: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/43.jpg)
2) Theophylline:-Bronchodilator & now weak anti-inflammatory.-Weak bronchodilator compared with beta2 agonists.-Administered p.o., I.V., or rectally.
-Therapeutic range: 5-15ug/ml.
* Addition of theophylline to optimal inhaled SABA + systemic corticosteroid in E.R. or hospital showed NO added benefit for acute severe asthma over optimal beta2 agonist + systemic corticosteroid alone.
![Page 44: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/44.jpg)
• I.V. theophylline: Reserved for those who fail to respond to high-dose inhaled SABA + systemic corticosteroid in severe acute asthma.
• Role of theophylline in chronic asthma is reduced because: - New agents (LABA)
- Its addition has similar efficacy as increasing the ICS dose.
**Theophylline is reserved as a second line add-on treatment for chronic persistent asthma.
![Page 45: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/45.jpg)
3) Anticholinergics:• Ipratropium Bromide: -Short-Acting (4-8hrs) - Less bronchodilation than beta-2 agonists. • Guidelines recommend the use nebulized
Ipratropium in combination with beta-2 agonists for the treatment of acute severe asthma in those who fail to respond to initial treatment with SABA.
• Guidelines do NOT include anticholinergic therapy in the management of chronic asthma (more effective meds. available).
![Page 46: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/46.jpg)
II. Anti-inflammatory Agents:1) Cromolyn Na/ Nedocromil:• Not used for acute asthma.• Dosed 3 or 4 X daily.• Inhibit IAR & LAR• Prevent EIA (lesser extent than inhaled beta2
agonists) if used 15-30min. before exposure.• Clinical effects are seen within 1 wk. of starting
therapy & 4 wks. are required to determine efficacy.• Guidelines recommend Cromolyn& Nedocromil as
2nd-line therapy only in mild persistent asthma in children & adults.
![Page 47: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/47.jpg)
2) Leukotriene Modifiers: (Newest Class):*(Zileuton:QID, Zafirlukast:BID, Montelukast:QD)*Reduce IAR & LAR.*All administered p.o.• Montelukast: Given @ bedtime to reach highest
serum conc. during the night & early morning hours when symptoms tend to be worse.
*Zafirlukast: Bioavailability sig. reduced w/ food.*Zileuton: Sig.DI profile& liver toxicity.
![Page 48: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/48.jpg)
• Montelukast:• Preferred because:
1) Once daily dosing.2) Lack of drug & food interaction.3) The only one approved for children
as young as 1 y.o.
*Montilukast + ICS has similar efficacy as doubling ICS dose.
![Page 49: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/49.jpg)
• Guidelines currently recommend Leukotriene Modifier :
1) As single drug therapy for mild-persistent asthma (step2) as alternative after therapy with ICS has been considered.
2) As 2nd line therapy in moderate-persistent asthma (step3) after LABA as add-on therapy to ICS.
**Greatest advantage is the ORAL dosage form.
![Page 50: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/50.jpg)
3) Corticosteroids:• Most potent anti-inflammatory used in asthma
treatment.A) ICS:• ICS : The most effective long-term control therapy for
persistent asthma.
• ICS use is assoc. w/ :1. Reduced risk of hospit. & acute exacerbation.2. Offers the only long-term
control therapy assoc. w/ reduced risk of dying from asthma.
![Page 51: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/51.jpg)
• Gargling w/ water & spitting immediately after DPI ICS may reduce the GI.
• Both:1) Gargling & 2) Use of VHC w/MDI
Reduce local ADRs i.e. oropharyngeal thrust & hoarseness.
* More potent ICSs are preferred due to lower doses used.
See table 34.5 for Doses of ICSs
![Page 52: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/52.jpg)
• Most patients are treated w/ low-med. doses.
• High doses have greater potential for systemic S/Es.
• Growth suppression or growth retardation were reported w/ low-med doses ICS w/ only small effect (1-2 cm in 1 yr) w/ final adult height not affected.
• It is recommended for children on ICS to have their heights monitored routinely.
• Only those on high doses ICS must have their bone mineral density & HPA- Axis monitored.
![Page 53: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/53.jpg)
• Dosing ICS is initially based on severity.
• Usual recommendation is for ICS to be adm. BID.
• Many with mild cases may be controlled on QD in late afternoon or evening.
• ICS + LABA can reduce the ICS dose, & can have greater efficacy than doubling the ICS dose.
• LABA can not replace ICS due to lack of anti-inflammatory effect.
![Page 54: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/54.jpg)
B) Systemic Corticosteroids: (Rescuer & Controller)• Rescuers for acute asthma exacerbations.• Oral Prednisone & Prednisolone : Most commonly used w/
min. mineral corticoid activity.• No advantage of I.V. over oral in the onset or efficacy.• Higher doses are assoc. w/ more S/Es & NO greater benefit.
As rescuers, their use is recommended only for those NOT responding to initial 3 doses of inhaled SABA.
• The use of systemic corticosteroids for additional 7-10 days after discharge from E.R. to home may reducethe # of relapses , & the addition of ICS @ this time may produce added benefits.
* Most studies used dosage regimens from 3-10 days. (table 34.4)
![Page 55: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/55.jpg)
• Patients receiving 3-4 “short bursts” prednisone (≤ 10 d) did not show long-term corticosteroid toxicity.
• At least 8 bursts (@ least 10d each) showed similar reduction in mineral density as QD or QOD dosing.
• Those requiring > 3-4 courses prednisone should be replaced on appropriate long-term control therapy w/ ICS.
• Tapering may be unnecessary if started on ICS.
![Page 56: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/56.jpg)
III. Anti-IgE Monoclonal Antibodies:• Omalizumab : The 1st agent approved by FDA
in 2003 for pts. ≥ 12y.o.• Critical role in inflammatory process in allergic asthma.• SQ every 2-4 wks.• Dose calculated based on weight & baseline IgE.• Very expensive.• Effective in:1) Reducing allergic asthma exacerbations.2) Reducing steroid-dose in mod.-sev. allergic asthma.3) Increasing quality of life.
![Page 57: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/57.jpg)
• Potential for rare anaphylaxis, transient thrombocytopenia, urticatia, & risk of malignancy in the label.
** Reserved for patients with severe allergic asthma not adequately controlled with standard therapy.**
![Page 58: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/58.jpg)
***≥ 12% improvement in FEV1 after the administration of SABA is considered significant clinical reversibility.***
![Page 59: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/59.jpg)
![Page 60: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/60.jpg)
![Page 61: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/61.jpg)
![Page 62: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/62.jpg)
![Page 63: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/63.jpg)
![Page 64: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/64.jpg)
![Page 65: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/65.jpg)
![Page 66: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/66.jpg)
![Page 67: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/67.jpg)
![Page 68: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/68.jpg)
![Page 69: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/69.jpg)
![Page 70: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/70.jpg)
![Page 71: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/71.jpg)
![Page 72: Asthma](https://reader038.vdocuments.us/reader038/viewer/2022110402/56812b1a550346895d8f0c19/html5/thumbnails/72.jpg)